BSFA Stock Overview A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ANI Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ANI Pharmaceuticals Historical stock prices Current Share Price US$55.50 52 Week High US$64.00 52 Week Low US$47.80 Beta 0.74 1 Month Change 4.72% 3 Month Change 4.72% 1 Year Change 8.82% 3 Year Change 70.25% 5 Year Change -5.13% Change since IPO 1,069.16%
Recent News & Updates
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09 See more updates
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Nov 08
ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06% Oct 25
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others. Sep 17 Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement Sep 11
Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023) Aug 07
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Aug 06
ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder Jul 15
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index Jul 03
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP Jul 02 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. Jun 25
Senior VP of Finance & CFO recently sold €292k worth of stock Jun 09
President recently sold €1.0m worth of stock May 17
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 11
First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023) May 10
ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension Apr 10
ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024 Apr 06
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP Mar 27
Independent Director recently sold €420k worth of stock Mar 08
Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022) Mar 01
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024 Feb 08
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP Jan 24
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP Jan 16
Head of Rare Disease recently sold €148k worth of stock Nov 14
New minor risk - Share price stability Nov 10
Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023 Nov 09
ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares Oct 05
Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1% Aug 29
ANI Pharmaceuticals, Inc. Announces Board Changes Aug 24
President recently sold €3.0m worth of stock Aug 17
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022) Aug 10
Forecast breakeven date moved forward to 2023 Aug 10
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 10
ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 01
New minor risk - Profitability Jul 24 ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million. May 13
First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022) May 09 ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023
Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021) Mar 10
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP Dec 20
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP Nov 29
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP Nov 17
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021) Nov 10
Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022 Nov 10
ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 25
ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer Sep 13
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP Aug 30
Key Executive recently sold €661k worth of stock Aug 18
ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP Aug 17 ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022
Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021) Aug 08
Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP Aug 04
ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary Jul 19
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP Jun 02
ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: US$1.27 loss per share (vs US$0.007 profit in 1Q 2021) May 10
High number of new directors Apr 27
ANI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Misoprostol Tablets Apr 12
Chairman recently bought €126k worth of stock Mar 23
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
ANI Pharmaceuticals Announces Executive Changes Feb 25
ANI Pharmaceuticals, Inc., Annual General Meeting, Apr 27, 2022 Feb 16
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® Powder, Including 180 Days of Exclusivity Feb 15
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel for Multiple Chronic Autoimmune Disorders Jan 25
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP Dec 22
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc Announce Commercial Availability of Carglumic Acid Tablets Dec 21
Independent Director recently bought €87k worth of stock Dec 08
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Novitium Pharma LLC. Nov 24
ANI Pharmaceuticals, Inc. announced that it has received $25 million in funding from Ampersand Management LLC Nov 23
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.035 profit in 3Q 2020) Nov 04
ANI Pharmaceuticals, Inc. Announces Launch of Nebivolol Tablets Sep 20
Ani Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome Sep 02
Second quarter 2021 earnings released: US$1.17 loss per share (vs US$1.03 loss in 2Q 2020) Aug 08 ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Growth Index
First quarter 2021 earnings released: EPS US$0.007 (vs US$0.59 loss in 1Q 2020) May 08 Shareholder Returns BSFA DE Pharmaceuticals DE Market 7D 1.8% 1.5% 1.9% 1Y 8.8% -7.6% 15.1%
See full shareholder returns
Return vs Market: BSFA underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is BSFA's price volatile compared to industry and market? BSFA volatility BSFA Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BSFA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BSFA's weekly volatility (5%) has been stable over the past year.
About the Company ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.
Show more ANI Pharmaceuticals, Inc. Fundamentals Summary How do ANI Pharmaceuticals's earnings and revenue compare to its market cap? BSFA fundamental statistics Market cap €1.10b Earnings (TTM ) -€8.46m Revenue (TTM ) €535.85m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BSFA income statement (TTM ) Revenue US$555.46m Cost of Revenue US$223.35m Gross Profit US$332.11m Other Expenses US$340.87m Earnings -US$8.77m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.45 Gross Margin 59.79% Net Profit Margin -1.58% Debt/Equity Ratio 145.2%
How did BSFA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 00:57 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ANI Pharmaceuticals, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Dewey Steadman Canaccord Genuity Louise Chen Cantor Fitzgerald & Co. Timothy Chiang Capital One Securities, Inc.
Show 10 more analysts 
